New-generation diabetes management: glucose sensor-augmented insulin pump therapy

被引:0
作者
Cengiz, Eda [1 ]
Sherr, Jennifer L. [1 ]
Weinzimer, Stuart A. [1 ]
Tamborlane, William V. [1 ]
机构
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
基金
美国国家卫生研究院;
关键词
artificial pancreas; closed-loop; continuous glucose monitors; continuous subcutaneous insulin infusion; diabetes; sensor-augmented pump therapy; MONITORING-SYSTEM; BLOOD-GLUCOSE; PEDIATRIC-PATIENTS; INFUSION; CHILDREN; ACCURACY; ADOLESCENTS; LOOP; HYPOGLYCEMIA; PERFORMANCE;
D O I
10.1586/ERD.11.22
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Diabetes is one of the most common chronic disorders with an increasing incidence worldwide. Technologic advances in the field of diabetes have provided new tools for clinicians to manage this challenging disease. For example, the development of continuous subcutaneous insulin infusion systems have allowed for refinement in the delivery of insulin, while continuous glucose monitors provide patients and clinicians with a better understanding of the minute to minute glucose variability, leading to the titration of insulin delivery based on this variability when applicable. Merging of these devices has resulted in sensor-augmented insulin pump therapy, which became a major building block upon which the artificial pancreas (closed-loop systems) can be developed. This article summarizes the evolution of sensor-augmented insulin pump therapy until present day and its future applications in new-generation diabetes management.
引用
收藏
页码:449 / 458
页数:10
相关论文
共 65 条
[1]  
Ahern Jo Ann H, 2002, Pediatr Diabetes, V3, P10
[2]   Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems [J].
Anhalt, Henry ;
Bohannon, Nancy J. V. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 :S51-S58
[3]  
[Anonymous], PARADIGM VEO
[4]  
[Anonymous], FDA SUMM SAF EFF DAT
[5]  
[Anonymous], COPILOT FREESTYLE NA
[6]  
[Anonymous], DEXCOM 7 PLUS SOFTW
[7]  
[Anonymous], FEASIBILITY STUDY AS
[8]  
[Anonymous], MINIMED PARADIGM VEO
[9]  
[Anonymous], INT SOC PED AD DIAB
[10]  
[Anonymous], DIABETES TECHNOL THE